安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2 . . .
HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC) This phase II study investigated efficacy and safety of the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC
- HER2 alterations in non-small cell lung cancer (NSCLC . . . - Frontiers
In our comprehensive review, we outline the molecular biology of HER2 in NSCLC, including distinctions between HER2 mutations, amplification, and overexpression, and we delve into the diverse diagnostic complexities
- Trastuzumab emtansine (T-DM1) in advanced cancers with
Background: The antibody-drug conjugate T-DM1 is widely used for the treatment of HER2-positive metastatic breast cancer Its activity in other advanced solid tumors harboring HER2 alterations identified by comprehensive genomic profiling (CGP) needs further characterization
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2 . . .
This phase II study investigated efficacy and safety of the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC
- Targeting HER2 alterations in non-small cell lung cancer: Therapeutic . . .
In this article, we review the recent progress in anti-HER2 agents, highlight the current challenges of these novel therapeutic strategies, and discuss future efforts to make a next breakthrough in the treatment of NSCLC with HER2 alterations
- A signal-seeking phase 2 study of Trastuzumab emtansine in . . . - Nature
Within another multi-histology basket trial of T-DM1 (NCT02675829) the salivary gland cohort (n = 10) with HER2 amplified tumours demonstrated an ORR of 90%, including five complete
- Targeting HER2 in lung cancers: Evolving treatment landscape and drug . . .
Several mechanisms of HER2 dysregulation that promote oncogenic transformation have been identified in NSCLC (Figure 1) These include activating mutations, mainly insertion mutations clustered in exon 20, gene amplification, and overexpression of the HER2 protein on tumor cell surfaces
- Clinical outcomes for patients who received both trastuzumab deruxtecan . . .
METHODS We conducted a single-center retrospective study of patients with HER2 -mutant NSCLC who received both T-DXd and T-DM1 in either order Clinical characteristics, confirmed overall response rate (ORR), real-world progression-free survival (rwPFS), and overall survival (OS) were evaluated
|
|
|